Dose-Dependent Effect of Estrogen Suppresses the Osteo-Adipogenic Transdifferentiation of Osteoblasts via Canonical Wnt Signaling Pathway
Figure 3
Dose-dependent estrogen on osteogenic markers of osteo-adipogenic transdifferentiation of BMMSCs derived osteoblasts.
After 14 days’ osteogenesis, different concentrations of 17beta-estradiol were added in adipogenic medium for 14 days and 14 days’ osteogenesis of BMMSCs in OVX group was used as positive control. O14∶14 days’ osteogenesis; O14+A7∶7 days’ adipogenesis after 14 days’ osteogenesis; O14+A14∶14 days’ adipogenesis after 14 days’ osteogenesis; E210−8 M: 14 days’ adipogenesis accompanied with 10−8 M of 17beta-estradiol after 14 days’ osteogenesis; E25×10−8 M: 14 days’ adipogenesis accompanied with 5×10−8 M of 17beta-estradiol after 14 days’ osteogenesis; E210−7 M: 14 days’ adipogenesis accompanied with 10−7 M of 17beta-estradiol after 14 days’ osteogenesis; E25×10−7 M: 14 days’ adipogenesis accompanied with 5×10−7 M of 17beta-estradiol after 14 days’ osteogenesis. A: ALP staining of osteo-adipogenic transdifferentiation of BMMSCs. B: ALP activity of osteo-adipogenic transdifferentiation of BMMSCs. The control value for ALP activity was 0.782±0.019 unit/mg protein. C: Alizarin red staining of osteo-adipogenic transdifferentiation of BMMSCs. D: The mineralization of osteo-adipogenic transdifferentiation of BMMSCs. The control value for mineralization was 0.985±0.020 OD. Data are represented as mean±SD of 3 independent experiments. *P<0.05 and **P<0.01.